2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion
Open Access
- 26 January 2022
- Vol. 27 (3), 804
- https://doi.org/10.3390/molecules27030804
Abstract
Ovarian cancer (OC) is the second most common type of gynecological malignancy. Platinum (Pt)-based chemotherapy is the standard of care for OC, but toxicity and acquired chemoresistance has proven challenging. Recently, we reported that sensitivity to platinum was significantly reduced in a co-culture of OC cells with MSC. To discover compounds capable of restoring platinum sensitivity, we screened a number of candidates and monitored ability to induce PARP cleavage. Moreover, we monitored platinum uptake and expression of ABC transporters in OC cells. Our results showed that 2-hydroxyestradiol (2HE2), a metabolite of estradiol, and dasatinib, an Abl/Src kinase inhibitor, were significantly effective in overcoming MSC-mediated platinum drug resistance. Dasatinib activity was dependent on ERK1/2 activation, whereas 2HE2 was independent of the activation of ERK1/2. MSC-mediated platinum drug resistance was accompanied by reduced intracellular platinum concentrations in OC cells. Moreover, MSC co-cultured with OC cells resulted in downregulation of the expression of cellular transporters required for platinum uptake and efflux. Exposure to 2HE2 and other modulators resulted in an increase in intracellular platinum concentrations. Thus, 2HE2 and dasatinib might act as sensitizers to restore platinum drug sensitivity to OC cells and thus to limit TME-mediated chemoresistance in OC.Funding Information
- Israeli Ministry of Health (3-0000-15095)
This publication has 73 references indexed in Scilit:
- Mesenchymal stem cells enhance ovarian cancer cell infiltration through IL6 secretion in an amniochorionic membrane based 3D modelJournal of Translational Medicine, 2013
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences of the United States of America, 2010
- Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitorsNature, 2010
- Copper Transporter 2 Regulates the Cellular Accumulation and Cytotoxicity of Cisplatin and CarboplatinClinical Cancer Research, 2009
- Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese populationPharmacogenetics and Genomics, 2009
- Migratory neighbors and distant invaders: tumor-associated niche cellsGenes & Development, 2008
- Evidence for functional redundancy of class IA PI3K isoforms in insulin signallingBiochemical Journal, 2007
- Stromal fibroblasts in cancer initiation and progressionNature, 2004
- The Orally Available Spleen Tyrosine Kinase Inhibitor 2-[7-(3,4-Dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide Dihydrochloride (BAY 61-3606) Blocks Antigen-Induced Airway Inflammation in RodentsThe Journal of pharmacology and experimental therapeutics, 2003
- Specificity and mechanism of action of some commonly used protein kinase inhibitorsBiochemical Journal, 2000